pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 95

Biopharma Sales Prescription FDA 95

PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. Figure 1: Share of net spending for specialty and traditional prescription medications. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

Prescription 52

Prescription Medical Patients Distribution 52

PM360

APRIL 7, 2023

This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. Given the volume of 340B sales (13% of total U.S. Quality and value measurements commonly used outside of the U.S. The 340B battle will rage on.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

pharmaphorum

JUNE 29, 2022

The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026.

Doctors 59

Doctors Medicine Marketing Sales 59